Same Result, Different Price: Compounded versus Branded Tirzepatide

Branded and compounded tirzepatide show statistically equivalent effectiveness in weight loss, making the choice largely a cost decision based on the patient's insurance coverage.

Summary and findings

This study compared the effectiveness and cost of compounded tirzepatide versus branded formulations in a cohort of patients. The primary outcome measured was six-month percent body weight loss among 7,271 patients, with results showing no significant difference between the two formulations. Cost savings varied depending on the branded price scenario faced by patients.

Abstract

<h4>Background</h4> Compounded tirzepatide is prescribed at scale as a cheaper substitute for branded Mounjaro and Zepbound, yet the cost case is almost always built by setting one compounded price against one branded list price. That framing ignores the question that actually decides the answer: cheaper than which branded price the patient can reach. Branded tirzepatide is now sold at sharply different tiers, namely insurance copay (often $25–$150/month), LillyDirect Self Pay ($299–$449/month), and retail cash price ($1,000–$1,200/month). Whether compounded saves money turns entirely on which of these a given patient faces. A second open question is whether the two formulations even produce comparable effectiveness, since observed differences may reflect selection on insurance, baseline characteristics, and adherence rather than the drug. <h4>Methods</h4> We conducted a retrospective cohort study of tirzepatide users in the Mochi Health tele-health program, classified by formulation from their refills as branded-only (Mounjaro/Zepbound; 6,238), compounded-only (71,683), or switchers (4,996); switchers were excluded from the formulation contrast. Among single-formulation patients with a documented six-month weight observation, the analytic cohort was 7,271 (869 branded, 6,402 compounded). The primary outcome was six-month percent body weight loss; the secondary outcome was ≥ 10% response. We used 1:1 nearest-neighbor propensity-score matching (0.25 SD caliper) on baseline covariates only — age, sex, baseline BMI, baseline weight, comorbid diabetes, hypertension, dyslipidemia, prior bariatric surgery, and self-reported insurance coverage — deliberately excluding post-treatment variables such as adherence and time in program, which are mediators of the formulation effect. We pre-specified an equivalence margin of ± 2 percentage points on mean loss and tested equivalence with two one-sided tests (TOST). A directed acyclic graph (DAG) makes the identifying assumptions explicit; metformin use could not be reliably ascertained and is treated as an unmeasured confounder. The cost comparison reports the savings or premium of compounded versus branded under five branded price scenarios: retail list, LillyDirect Self Pay (two dose tiers), and insurance copay (typical and low end). It is a cost comparison (cost-minimization under demonstrated similar effectiveness), not a formal cost-effectiveness analysis: we computed no ICER, QALY, or discounting. <h4>Results</h4> Branded and compounded patients had similar outcomes even before adjustment (mean loss 11.7% vs 11.5%; ≥ 10% response 60.9% vs 58.8%). The largest baseline difference between the groups was insurance coverage (branded patients far more likely insured; standardized mean difference 0.67), which matching balanced to 0.01. After 1:1 matching (718 pairs, all |SMD| < 0.04), mean loss was 11.4% vs 11.4% (difference +0.08 pp, 95% CI −0.70 to +0.80) and ≥ 10% response 59.3% vs 57.2% (difference +2.1 pp, 95% CI −3.1 to +7.1). The two formulations were statistically equivalent within the pre-specified ± 2 pp margin (TOST p < 0.001). Cost depends on the branded scenario: compounded saves $6,000 over six months versus retail list price, $1,494 versus LillyDirect maintenance-dose (5–15 mg) Self Pay, and $594 over a low-dose (2.5 mg) LillyDirect prescription, while it costs $300 more than branded under a typical insurance copay ($150/month) and is more expensive still at lower copays (savings turn negative below $200/month). <h4>Conclusions</h4> Branded and compounded tirzepatide were statistically equivalent in six-month effectiveness within a pre-specified ± 2 pp margin, so the choice between them is essentially a cost decision — and that cost advantage is real but conditional on the branded price the patient can access. It is large against retail list price and shrinks to zero or reverses against LillyDirect Self Pay or a low insurance copay. Whether compounded is the lower-cost choice for an individual patient is, therefore, a question about which price tier that patient faces.

Key findings

• Not reported in abstract.

Limitations

• Not reported in abstract.

Elsewhere in the Tirzepatide corpus